Cost-effectiveness analysis of liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas in Greece.
| Publicado en: | Expert Review of Pharmacoeconomics & Outcomes Research pp. 1 - 10 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
Taylor & Francis Ltd
Aug2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |